Physician profile
Drew Michael Johnson
NPI 1205222163
$1,205.48
in general payments reported to CMS, 2019-2025
15 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $287 · 2021: $180 · 2022: $36.01 · 2023: $59.72 · 2024: $143 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $613.25 | 2019-2024 | Pressurewire, Coroflow |
| Novartis Pharmaceuticals Corporation | $85.19 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.93 | 2024-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $63.66 | 2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.15 | 2025 | Jardiance |
| Amgen INC. | $55.50 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $55.32 | 2019-2025 | Eliquis |
| Pfizer INC. | $51.45 | 2020-2022 | |
| Boston Scientific Corporation | $24.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.32 | 2021 | |
| Philips North America LLC | $23.60 | 2024 | (Ck4) Mcot |
| Novo Nordisk INC | $22.02 | 2024 | Wegovy |
| Daiichi Sankyo INC. | $21.58 | 2023 | Injectafer |
| Cardiovascular Systems INC. | $17.76 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.